This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A therapeutic composition comprising 0.5 mg to 750 mg of a drug of the formula:



wherein the dotted line represents an unsaturation or a cycloalkenyl group; R_1 is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R_2 is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R_4 is a member selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, formyl, and alkanoyl of 2 to 7 carbon atoms; R_5 and R_6 are independently a member selected from the group consisting of hydrogen, hydroxyl and alkyl of 1 to 6 carbon atoms, an alkoxy of 1 to 6 carbon atoms, alknaoyloxy of 2 to 7 carbon atoms, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms in which each alkyl group comprises 1 to 6 carbon atoms, alkanamide of 2 to 7 carbon atoms, halo and triflouroethyl; R_7 is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbons; and n is one of the integers 0, 1, 2, 3, and 4, and a pharmaceutically acceptable addition salt; and wherein the drug of the formula is blended with a poly(alkylene oxide) polymer.

Claims 2-7 (canceled)

Claim 8 (new): A controlled-release dosage form for the oral delivery of a drug to an environment of use, wherein the dosage form comprises:

(a) a wall comprising at least in part a composition permeable to the passage of fluid, which wall surrounds;

(b) a compartment;

(c) a drug composition in the compartment comprising a drug of the formula:



wherein the dotted line represents a member selected from the group consisting of an unsaturation and cycloalkenyl group; R_1 is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R_2 is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R_4 is a member selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, formyl, and alkanoyl of 2 to 7 carbon atoms; R_5 and R_6 are independently a member selected from the group consisting of hydrogen, hydroxyl and alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alknacyloxy of 2 to 7 carbon atoms, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms, alkanamide of 2 to 7 carbon atoms, halo and trifluoroethyl; R_7 is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbons; and n is 0 to 4; and

(d) a displacement in the compartment comprising a composition comprising an osmotically active compound; and,

(e) an exit passageway in the dosage form for delivering the drug composition from the dosage form in a controlled-release manner.

Claim 9 (new): A controlled-release dosage form for the oral delivery of 1-[2-(dimethylamino)-1-(4-methoxyphenal)ethyl]-cyclohexanol to a patient, wherein the dosage form comprises:

(a) a wall comprising a semipermeable composition permeable to the passage of fluid, which wall surrounds;

(b) a compartment;

(c) a therapeutic composition in the compartment comprising 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol;

(d) a displacement composition in the compartment comprising an osmotically effective compound; and

(e) an exit passageway in the dosage form for delivering the 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol from the dosage form in a controlled-release manner.